图书馆订阅: Guest
医药载体系统评论综述

每年出版 6 

ISSN 打印: 0743-4863

ISSN 在线: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine’s Drug Conjugates on Cancer Therapy

卷 34, 册 1, 2017, pp. 63-96
DOI: 10.1615/CritRevTherDrugCarrierSyst.2017017912
Get accessGet access

摘要

Currently, drug delivery systems have a high impact in cancer therapy and are receiving more attention than conventional cancer treatment modalities. Compared with current cancer therapies, gemcitabine (2', 2'-difluoro-2'-deoxycytidine) has been proven to be an effective chemotherapeutic agent against pancreatic, colon, bladder, breast, ovarian, non-small-cell lung, and head and neck cancers in combination with other anticancer agents. To improve the safety and efficacy of cytotoxic drugs, several drug delivery systems have been explored. This review outlines the recent work directed toward gemcitabine delivery systems for cancer therapy, including aerosols, polymeric nanoparticles, liposomes, microparticles, carbon nanotubes, and multifunctional theranostic nanomedicines. It also provides insight into the design and development of gemcitabine conjugation for safe and effective cancer therapy. Despite the clinical promises of gemcitabine, many therapeutic challenges remain. Specifically, its therapeutic use in cancer chemotherapy is impeded by a short biological half-life, caused by its rapid metabolism, and resistance due to increased expression of ribonucleotide reductase. In our opinion, many research investigations have contributed to improve the selectivity and efficacy of gemcitabine. This combined approach of drug delivery systems and gemcitabine conjugates has shown promising efficacy in preclinical models and significant potential for future clinical cancer-therapeutic applications. Also, these strategies overcome most of the aforementioned limits of gemcitabine.

对本文的引用
  1. Chu Wei, Tian Pengqian, Ding Ning, Cai Qing, Li Jinlong, Zhuo Xuezhi, Tang Zhaohui, Gou Jingxin, Yin Tian, Zhang Yu, He Haibing, Tang Xing, Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate, Pharmaceutical Research, 35, 12, 2018. Crossref

  2. Sanomachi Tomomi, Suzuki Shuhei, Togashi Keita, Sugai Asuka, Seino Shizuka, Okada Masashi, Yoshioka Takashi, Kitanaka Chifumi, Yamamoto Masahiro, Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs, Cancers, 11, 10, 2019. Crossref

  3. Wang Qi, Xu Henglong, Warren Alan, A Bioassay for the Cytotoxicity of Gemcitabine Using the Marine Ciliate Euplotes vannus, Journal of Ocean University of China, 18, 3, 2019. Crossref

  4. Deng Dingmei, Ye Xian, Wang Xiyue, He Guangning, Retracted Article: Gemcitabine aggravates miR-199a-5p-mediated breast cancer cell apoptosis by promoting VEGFA downregulation via inactivating the AKT signaling pathway, RSC Advances, 9, 35, 2019. Crossref

  5. Park Jun Young, Chae Ju Ri, Cho Ye Lim, Kim Youndong, Lee Dasom, Lee Jeong Kyun, Kang Won Jun, Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer, Pharmaceutics, 12, 10, 2020. Crossref

  6. Ma Changpo , Shi Xuejun , Guo Wenchao , Feng Fukai , Wang Guangshun , miR‑205‑5p downregulation decreases gemcitabine sensitivity of breast cancer cells via ERp29 upregulation, Experimental and Therapeutic Medicine, 2019. Crossref

  7. Yang Shuzhang, Luo Danyan, Li Na, Li Chuncheng, Tang Shuo, Huang Zhen, New Mechanism of Gemcitabine and Its Phosphates: DNA Polymerization Disruption via 3′–5′ Exonuclease Inhibition, Biochemistry, 59, 45, 2020. Crossref

  8. Hawryłkiewicz Aleksandra, Ptaszyńska Natalia, Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy, Molecules, 26, 2, 2021. Crossref

  9. Prajapati Shiv Kumar, Jain Ankit, Shrivastava Chirag, Jain Ashish Kumar, Hyaluronic acid conjugated multi-walled carbon nanotubes for colon cancer targeting, International Journal of Biological Macromolecules, 123, 2019. Crossref

  10. Takemoto Hiroyasu, Inaba Takanori, Nomoto Takahiro, Matsui Makoto, Liu Xiaomeng, Toyoda Masahiro, Honda Yuto, Taniwaki Kaori, Yamada Naoki, Kim Junhyun, Tomoda Keishiro, Nishiyama Nobuhiro, Polymeric modification of gemcitabine via cyclic acetal linkage for enhanced anticancer potency with negligible side effects, Biomaterials, 235, 2020. Crossref

  11. Anand Uttpal, Dey Abhijit, Chandel Arvind K. Singh, Sanyal Rupa, Mishra Amarnath, Pandey Devendra Kumar, De Falco Valentina, Upadhyay Arun, Kandimalla Ramesh, Chaudhary Anupama, Dhanjal Jaspreet Kaur, Dewanjee Saikat, Vallamkondu Jayalakshmi, Pérez de la Lastra José M., Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics, Genes & Diseases, 2022. Crossref

  12. Tunki Lakshmi, Ganthala Parimala Devi, Pooja Deep, Andugulapati Sai Balaji, Kulhari Hitesh, Sistla Ramakrishna, Bhargava Suresh Kumar, Ameliorating the antitumor activity of gemcitabine against breast tumor using αvβ3 integrin-targeting lipid nanoparticles, Drug Development and Industrial Pharmacy, 2022. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain